Skip to content

Prospective Trial for Examining Hematuria Using Computed Tomography

Prospective Trial for Examining Hematuria Using Computed Tomography

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04077359
Acronym
PROTEHCT
Enrollment
300
Registered
2019-09-04
Start date
2019-09-15
Completion date
2021-07-01
Last updated
2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma, Renal Cyst, Renal Stone, Urothelial Carcinoma

Brief summary

The primary objective is to evaluate whether one-phase nephrographic CT (experimental) is sufficient to detect urothelial cell carcinoma in patients with hematuria compared to the traditional four-phase CT (control).

Detailed description

Responsible centers Oslo University Hospital, Aker. Division of Radiology and Nuclear medicine. Study type: Prospective clinical trial Study design: One sample paired proportion, non-inferiority study with a 7.5% non-inferiority limit. Investigational product: One phase nephrographic CT (experimental arm) vs. Four-phase CT (control arm) Objective:The primary objective is to evaluate whether one-phase nephrographic CT (experimental) is sufficient to detect urothelial cell carcinoma in patients with asymptomatic macroscopic hematuria compared to the traditional four-phase CT (control). Primary endpoints: The difference in accuracy between the experimental- and control arm. there will also be a secondary reading in order to asses interobserver variability for both the experimental and the control arm Sample size: 250 patients

Interventions

DIAGNOSTIC_TESTCT

the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

one investigator evaluates the experimental arm a second investigator evaluates the control arm without knowledge of the other

Intervention model description

One sample, paired, non-inferiority study with a 7.5% non-inferiority limit. Each patient undergo the experimental CT and the control CT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Asymptomatic macroscopic hematuria referred to CTU before cystoscopy * \>18 years old

Exclusion criteria

* Symptomatic urinary tract infection relieved by antibiotics * Patients referred to CTU after cystoscopy * Cystoscopy within the last 6 months * Symptomatic stone disease * Macroscopic hematuria after recent catherization or instrumentation * Microscopic hematuria * Previous history of Urothelial cell carcinoma * Known staghorn calculi * Allergy to iodine contrast media * Impaired renal function (eGFR \< 30m/min/1.73m2) * Unable to provide consent for any reason * For any reason, do not wish to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
accuracy for detecting urothelial cell carcinomasall examinations are evaluated immediately after the CT examination. Follow-up ascertainment of UCC diagnosis after one yearthe accuracy of the experimental arm will not be worse than the accuracy of the control CT by a margin of more than 7.5%

Secondary

MeasureTime frameDescription
false positive rateall examinations are evaluated immediately after the CT examinationThe difference in false positive rates
renal cell carcinoma detection ratesall examinations are evaluated immediately after the CT examination. Follow-up ascertainment of RCC diagnosis after one yearThe detection rates in the two arms
Area under the curve (AUC)all examinations are evaluated immediately after the CT examinationthe difference in AUC of the two arms
false negative rateall examinations are evaluated immediately after the CT examinationThe difference in false negative rates
Detection or urinary calculiall examinations are evaluated immediately after the CT examinationThe difference in detection of the two arms
Detection of Bosniak cystall examinations are evaluated immediately after the CT examinationThe difference in detection in the two arms
Interobserver variabilityall examinations are evaluated immediately after the CT examinationThe agreement and variability between primary and secondary readers
predictive valuesall examinations are evaluated immediately after the CT examinationThe difference in the predictive values of the two arms

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026